Goodman Financial Corp Makes New $11.49 Million Investment in Haleon PLC Sponsored ADR $HLN

Goodman Financial Corp acquired a new stake in Haleon PLC Sponsored ADR (NYSE:HLN) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 1,147,659 shares of the company’s stock, valued at approximately $11,488,000. Haleon makes up about 2.0% of Goodman Financial Corp’s holdings, making the stock its 25th biggest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Parkside Financial Bank & Trust raised its position in shares of Haleon by 101.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares during the last quarter. Stance Capital LLC bought a new position in Haleon in the third quarter valued at about $34,000. Geneos Wealth Management Inc. increased its position in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the period. Assetmark Inc. increased its position in Haleon by 26.6% in the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock worth $60,000 after purchasing an additional 1,252 shares during the period. Finally, Atlantic Union Bankshares Corp raised its holdings in Haleon by 69.4% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,264 shares of the company’s stock worth $63,000 after purchasing an additional 2,567 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Price Performance

Haleon stock opened at $10.12 on Friday. The firm has a market capitalization of $44.55 billion, a P/E ratio of 25.94, a PEG ratio of 2.25 and a beta of 0.13. Haleon PLC Sponsored ADR has a 1 year low of $8.65 and a 1 year high of $11.28. The business has a 50-day moving average of $9.25 and a 200-day moving average of $9.86. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Rothschild & Co Redburn downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Haleon presently has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.